{"id":"atezolizumab-injection","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Decreased appetite"},{"rate":"15–20","effect":"Nausea"},{"rate":"3–5","effect":"Immune-related pneumonitis"},{"rate":"2–4","effect":"Immune-related hepatitis"},{"rate":"1–3","effect":"Immune-related colitis"},{"rate":"15–20","effect":"Diarrhea"},{"rate":"10–15","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL3707227","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atezolizumab binds to programmed death ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors on T cells. This blockade restores exhausted T-cell function, allowing enhanced recognition and killing of cancer cells. By targeting PD-L1 rather than PD-1, it may also deplete PD-L1-expressing regulatory T cells and myeloid-derived suppressor cells.","oneSentence":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:51.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (NSCLC)"},{"name":"Metastatic urothelial carcinoma"},{"name":"Hepatocellular carcinoma"},{"name":"Gastric or gastroesophageal junction adenocarcinoma"},{"name":"Colorectal cancer (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":"Small Cell Lung Cancer","enrollment":180},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT05359861","phase":"PHASE2","title":"Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2022-04-12","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT03474094","phase":"PHASE2","title":"Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2018-08-01","conditions":"Sarcoma,Soft Tissue","enrollment":62},{"nctId":"NCT04081688","phase":"PHASE1","title":"Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2019-09-11","conditions":"Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":16},{"nctId":"NCT05733611","phase":"PHASE2","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","status":"TERMINATED","sponsor":"Replimune Inc.","startDate":"2023-06-29","conditions":"Refractory Metastatic Colorectal Cancer, pMMR, MSS","enrollment":5},{"nctId":"NCT07011004","phase":"PHASE1","title":"A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT05746481","phase":"PHASE2","title":"Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","status":"TERMINATED","sponsor":"Liza Villaruz, MD","startDate":"2023-08-10","conditions":"Non-small Cell Lung Cancer","enrollment":3},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT05450562","phase":"PHASE1, PHASE2","title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-09-20","conditions":"Neoplasm","enrollment":33},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT07226999","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-09","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":550},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT04796012","phase":"PHASE1, PHASE2","title":"VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Solid Tumor, Rhabdomyosarcoma","enrollment":23},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT05404048","phase":"PHASE2","title":"PD-L1 PET-imaging During CAR T-cell Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2022-05-18","conditions":"Large B-cell Lymphoma","enrollment":20},{"nctId":"NCT05836584","phase":"PHASE2","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-06","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":240},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03697850","phase":"PHASE2","title":"Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-12-14","conditions":"Bladder Cancer","enrollment":79},{"nctId":"NCT04396535","phase":"PHASE2","title":"Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-10-23","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":10},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT06182072","phase":"PHASE1","title":"ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"ProDa BioTech, LLC","startDate":"2023-09-14","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":46},{"nctId":"NCT04727307","phase":"PHASE2","title":"Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2021-02-23","conditions":"Hepatocellular Carcinoma","enrollment":202},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT02500407","phase":"PHASE1, PHASE2","title":"A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-09-15","conditions":"Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin","enrollment":713},{"nctId":"NCT03802604","phase":"EARLY_PHASE1","title":"Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2018-12-10","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT05109442","phase":"PHASE1, PHASE2","title":"Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers","status":"TERMINATED","sponsor":"Affimed GmbH","startDate":"2021-11-19","conditions":"Advanced Solid Tumor","enrollment":112},{"nctId":"NCT04477759","phase":"PHASE1","title":"Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2021-01-26","conditions":"Head and Neck Neoplasm","enrollment":18},{"nctId":"NCT05195619","phase":"PHASE1","title":"Personalized DC Vaccines in Non Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2022-03-22","conditions":"Non-small Cell Lung Cancer","enrollment":16},{"nctId":"NCT03502785","phase":"PHASE1, PHASE2","title":"INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-24","conditions":"Urothelial Carcinoma","enrollment":35},{"nctId":"NCT04975958","phase":"PHASE1","title":"Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Adlai Nortye Biopharma Co., Ltd.","startDate":"2021-09-07","conditions":"Locally Advanced Solid Tumor","enrollment":47},{"nctId":"NCT05118724","phase":"PHASE2","title":"Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIO-Studien-gGmbH","startDate":"2021-12-10","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT05253053","phase":"PHASE1, PHASE2","title":"To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2022-04-13","conditions":"Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer","enrollment":84},{"nctId":"NCT06067061","phase":"PHASE1, PHASE2","title":"\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Institut Curie","startDate":"2024-04-05","conditions":"Triple Negative Breast Neoplasms","enrollment":2},{"nctId":"NCT05870800","phase":"PHASE2","title":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2025-06-15","conditions":"Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer","enrollment":28},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06971237","phase":"","title":"SIRT and Peri-immunotherapy : a New Concept","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-01","conditions":"Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy","enrollment":60},{"nctId":"NCT06605664","phase":"PHASE2","title":"Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":45},{"nctId":"NCT04262154","phase":"PHASE2","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-03","conditions":"Metastatic Prostate Cancer","enrollment":28},{"nctId":"NCT05332561","phase":"PHASE2","title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","status":"RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-06-29","conditions":"Early-stage Breast Cancer","enrollment":240},{"nctId":"NCT05243862","phase":"PHASE2","title":"Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Treos Bio Limited","startDate":"2022-06-02","conditions":"Colorectal Cancer Metastatic","enrollment":18},{"nctId":"NCT04996017","phase":"PHASE3","title":"Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)","status":"RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2021-12-14","conditions":"Mesotheliomas Pleural","enrollment":162},{"nctId":"NCT04722575","phase":"PHASE2","title":"Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Melanoma Onlus","startDate":"2020-10-12","conditions":"Melanoma","enrollment":95},{"nctId":"NCT06867432","phase":"PHASE2","title":"Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT05776875","phase":"PHASE2","title":"Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC","status":"TERMINATED","sponsor":"Yale University","startDate":"2023-06-07","conditions":"Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT05007613","phase":"PHASE2","title":"Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-06-23","conditions":"Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT05456165","phase":"PHASE2","title":"Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer","status":"WITHDRAWN","sponsor":"Gritstone bio, Inc.","startDate":"2022-05-19","conditions":"Colonic Neoplasms, Colorectal Neoplasms","enrollment":""},{"nctId":"NCT05877430","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"CJ Bioscience, Inc.","startDate":"2023-09-11","conditions":"NSCLC, HNSCC, Melanoma","enrollment":160},{"nctId":"NCT06584071","phase":"PHASE1, PHASE2","title":"A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC","status":"NOT_YET_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2024-12","conditions":"HCC, Liver Cancer","enrollment":140},{"nctId":"NCT05018273","phase":"PHASE1","title":"Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors","status":"COMPLETED","sponsor":"Nykode Therapeutics ASA","startDate":"2021-12-21","conditions":"Solid Tumors, Adult","enrollment":26},{"nctId":"NCT03973333","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab","status":"WITHDRAWN","sponsor":"Immunocore Ltd","startDate":"2019-05-17","conditions":"Select Advanced Solid Tumors","enrollment":""},{"nctId":"NCT06099418","phase":"PHASE2","title":"Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.","status":"WITHDRAWN","sponsor":"Nykode Therapeutics ASA","startDate":"2024-04-18","conditions":"HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer","enrollment":""},{"nctId":"NCT03154827","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"BioLineRx, Ltd.","startDate":"2018-01-08","conditions":"Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT06006286","phase":"PHASE1, PHASE2","title":"A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-08","conditions":"Metastatic Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT04770207","phase":"PHASE2","title":"Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma, Solid Tumor, Adult","enrollment":100},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT04224636","phase":"PHASE2","title":"Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab","status":"RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2020-06-10","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":106},{"nctId":"NCT05765084","phase":"PHASE1, PHASE2","title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-02-24","conditions":"Malignant Pleural Mesothelioma","enrollment":15},{"nctId":"NCT03256344","phase":"PHASE1","title":"Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-03-19","conditions":"Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT04167137","phase":"PHASE1","title":"Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants","status":"TERMINATED","sponsor":"Synlogic","startDate":"2019-12-12","conditions":"Metastatic Solid Neoplasm, Lymphoma","enrollment":32},{"nctId":"NCT02453984","phase":"NA","title":"MPDL3280A-imaging-IST-UMCG","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2016-02-24","conditions":"Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression","enrollment":45},{"nctId":"NCT05260606","phase":"","title":"Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2022-05-09","conditions":"Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors","enrollment":100},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT06356701","phase":"PHASE1","title":"Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2024-04-15","conditions":"Long-Term Effects Secondary to Cancer Therapy","enrollment":120},{"nctId":"NCT04487756","phase":"PHASE1, PHASE2","title":"Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2021-03-17","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04793399","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients","status":"TERMINATED","sponsor":"Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica","startDate":"2021-02-24","conditions":"Chronic Phase-Chronic Myeloid Leukemia","enrollment":9},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT06169904","phase":"","title":"B7-Family Score in Urothelial Carcinoma","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2012-01-25","conditions":"Urothelial Carcinoma","enrollment":215},{"nctId":"NCT03555149","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-27","conditions":"Colorectal Cancer","enrollment":96},{"nctId":"NCT03390296","phase":"PHASE1, PHASE2","title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-27","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT02919449","phase":"PHASE1","title":"Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab","status":"TERMINATED","sponsor":"Vyriad, Inc.","startDate":"2017-08-03","conditions":"Recurrent Non-Small Cell Lung Cancer","enrollment":2},{"nctId":"NCT04471415","phase":"PHASE1, PHASE2","title":"Study to Investigate DRP-104 in Adults With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Dracen Pharmaceuticals, Inc.","startDate":"2020-08-31","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic","enrollment":61},{"nctId":"NCT03618953","phase":"PHASE1","title":"This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers","status":"TERMINATED","sponsor":"Turnstone Biologics, Corp.","startDate":"2018-06-21","conditions":"HPV-Associated Cancers","enrollment":8},{"nctId":"NCT05809336","phase":"PHASE2, PHASE3","title":"Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2019-05-01","conditions":"Advanced Solid Tumor","enrollment":172},{"nctId":"NCT04045028","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2019-07-22","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma","enrollment":41},{"nctId":"NCT03073525","phase":"PHASE2","title":"A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers","status":"COMPLETED","sponsor":"Gradalis, Inc.","startDate":"2017-05-31","conditions":"Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer","enrollment":25},{"nctId":"NCT02890368","phase":"PHASE1","title":"Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-09","conditions":"Solid Tumors, Mycosis Fungoides, Melanoma","enrollment":56},{"nctId":"NCT04059887","phase":"PHASE4","title":"Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2019-12-18","conditions":"Lung Neoplasm Malignant","enrollment":100},{"nctId":"NCT04186013","phase":"PHASE2","title":"Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2019-09-18","conditions":"Bladder Cancer","enrollment":39},{"nctId":"NCT04222426","phase":"NA","title":"89Zr-atezolizumab PET Scan and Lobular Breast Cancer","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2019-12-18","conditions":"Lobular Metastatic Breast Cancer","enrollment":1},{"nctId":"NCT05396937","phase":"PHASE2","title":"Efficacy and Safety of T+A+RAD in HCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-01-12","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT03628716","phase":"PHASE2","title":"CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2018-09-18","conditions":"Bladder Cancer","enrollment":43},{"nctId":"NCT03050814","phase":"PHASE2","title":"Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-05","conditions":"Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":30},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":"Soft Tissue Sarcoma Adult","enrollment":23},{"nctId":"NCT04020094","phase":"PHASE2","title":"Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2019-11-20","conditions":"Prostate Adenocarcinoma","enrollment":""},{"nctId":"NCT03892525","phase":"PHASE1","title":"Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma","status":"TERMINATED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2019-07-04","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":4},{"nctId":"NCT03721679","phase":"PHASE1, PHASE2","title":"Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1","status":"TERMINATED","sponsor":"Oncovir, Inc.","startDate":"2018-09-25","conditions":"Solid Cancer","enrollment":7},{"nctId":"NCT04670107","phase":"PHASE1, PHASE2","title":"The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2018-06-01","conditions":"NSCLC, Angiogenesis, Immunotherapy","enrollment":30},{"nctId":"NCT02423863","phase":"PHASE2","title":"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®","status":"COMPLETED","sponsor":"Oncovir, Inc.","startDate":"2015-03","conditions":"Melanoma, Head and Neck Cancer, Sarcoma","enrollment":26},{"nctId":"NCT04272645","phase":"PHASE2","title":"Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-10","conditions":"Prostate Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atezolizumab","Tecentriq"],"phase":"phase_3","status":"active","brandName":"Atezolizumab Injection","genericName":"Atezolizumab Injection","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity. Used for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}